u/Junior_Scale5592

I’ve been noticing that a lot of young male pts (early 20s to early 40s) who get referred to my ACT team from inpatient units carry an ASPD dx. Long-term therapeutic work reveals a pathology more consistent with mixed borderline/narcissistic traits, often exacerbated by substance use and chronically poor coping skills. I often find myself frustrated on behalf of my pts—once the ASPD dx shows up in the EHR it just gets copy/pasted during any subsequent hospitalizations, damaging potential therapeutic rapport with clinicians at the hospital and perhaps unnecessarily stigmatizing the pt.

I am starting to consider that traits more consistent with other cluster B disorders can be easily misrecognized as ASPD in men, especially because BPD has a gendered component. Has anyone else noticed a similar phenomenon, especially on the inpatient side? Or do I have a limited conceptualization of ASPD and it is affecting my observations? Or both? Or is there an answer adjacent to my question that could give me better insight into the diagnosis and treatment of PDs? Anecdotes and literature are both greatly appreciated!

I am a social worker on an ACT team in a large US city. Many of our patients have a primary psychotic disorder and a history of medication non-adherence, either by choice or due to their level of organization/functioning. As a result, most of them are on an LAI (mostly Invega, Uzedy, and Abilify with some Haldol and Prolixin mixed in) by the time they are enrolled with us.

There is an overlapping subset of patients (all of them currently on LAIs) we work with who have been on clozapine while hospitalized at one point in the course of their illness. These patients either a) have moderate to good insight but stop taking clozapine once they return to the community for any number of reasons or b) have little to no insight but receive court-mandated outpatient treatment that only requires adherence with an LAI as the standard for compliance.

For this subset of patients—those who can’t take clozapine due to their inability to consistently take oral meds and/or those who won’t take clozapine because of impaired judgement/insight—I can imagine that an LAI formulation would be incredibly beneficial. So many of them have cycled through multiple different antipsychotics and still experience a profound symptom burden.

So, why hasn’t a clozapine LAI been developed? Granted, I am not a psychiatrist and have a limited working knowledge of psychopharmacology, so there could be an obvious answer here that I am missing. But I am surprised that a medication viewed as the gold-standard for treatment-resistant schizophrenia is not available in an LAI form. Does anyone have insight into why this is?